Paul T Quinlan
CIK 1333277 · General Counsel · last filed 2026-03-17
Paul T Quinlan is a General Counsel who has filed 66 SEC Form 4 insider transactions across 3 companies since 2016. The most recent filing shows the insider sold $30.3K of ORKA on Mar 17, 2026. Across all open-market trades the lifetime net is −$1.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.22M
3
66
-$1.59M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ORKA | General Counsel | 31,767 | $69.89 | $2.22M | -$30.3K | 3 | 2026-03-17 |
| CymaBay Therapeutics, Inc. (CBAY) Delisted | General Counsel | 0 | $32.48 | $0 | -$1.50M | 18 | 2024-03-22 |
| TerraVia Holdings, Inc. (TVIA) Delisted | General Counsel | 218,403 | — | — | -$58.2K | 5 | 2017-03-13 |
Recent Filings
66 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-17 | ORKA | Sell (S) | −733 | -$30.3K | EDGAR |
| 2026-01-23 | ORKA | Grant (A) | +32,500 | $0 | EDGAR |
| 2025-01-24 | ORKA | Grant (A) | — | $0 | EDGAR |
| 2024-03-22 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Disp (D) | −70,262 | $0 | EDGAR |
| 2024-03-15 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Exer (M) | +41,824 | $330.0K | EDGAR |
| 2024-01-26 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Grant (A) | +28,438 | $0 | EDGAR |
| 2024-01-16 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Mixed | — | -$103.2K | EDGAR |
| 2023-12-15 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Mixed | — | -$95.2K | EDGAR |
| 2023-11-17 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Mixed | — | -$72.2K | EDGAR |
| 2023-10-18 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Mixed | — | -$54.1K | EDGAR |